<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="cfr.xsl"?>
<CFRGRANULE xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="CFRMergedXML.xsd">
  <FDSYS>
    <CFRTITLE>45</CFRTITLE>
    <CFRTITLETEXT>Public Welfare</CFRTITLETEXT>
    <VOL>1</VOL>
    <DATE>2001-10-01</DATE>
    <ORIGINALDATE>2001-10-01</ORIGINALDATE>
    <COVERONLY>false</COVERONLY>
    <TITLE>Modification or waiver of specific requirements.</TITLE>
    <GRANULENUM>46.211</GRANULENUM>
    <HEADING>Section 46.211</HEADING>
    <ANCESTORS>
      <PARENT HEADING="Title 45" SEQ="4">Public Welfare</PARENT>
      <PARENT HEADING="SUBTITLE A" SEQ="3">DEPARTMENT OF HEALTHAND HUMAN SERVICES</PARENT>
      <PARENT HEADING="SUBCHAPTER A" SEQ="2">GENERAL ADMINISTRATION</PARENT>
      <PARENT HEADING="PART 46" SEQ="1">PROTECTION OF HUMAN SUBJECTS</PARENT>
      <PARENT HEADING="Subpart B" SEQ="0">Additional Protections Pertaining to Research, Development, and Related Activities Involving Fetuses, Pregnant Women, and Human In Vitro Fertilization</PARENT>
    </ANCESTORS>
  </FDSYS>
  <SECTION>
    <SECTNO>§ 46.211</SECTNO>
    <SUBJECT>Modification or waiver of specific requirements.</SUBJECT>

    <P>Upon the request of an applicant or offeror (with the approval of its Institutional Review Board), the Secretary may modify or waive specific requirements of this subpart, with the approval of the Ethical Advisory Board after such opportunity for public comment as the Ethical Advisory Board considers appropriate in the particular instance. In making such decisions, the Secretary will consider whether the risks to the subject are so outweighed by the sum of the benefit to the subject and the importance of the knowledge to be gained as to warrant such modification or waiver and that such benefits cannot be gained except through a <PRTPAGE P="119"/>modification or waiver. Any such modifications or waivers will be published as notices in the <E T="04">Federal Register</E>.</P>
    <EAR>Pt. 46, Subpt. B, Note</EAR>
    <EFFDNOTP>
      <HD SOURCE="HED">Effective Date Note:</HD>
      <P>At 66 FR 3882, Jan. 17, 2001, subpart B was revised, effective Mar. 19, 2001. At 66 FR 15352, Mar. 19, 2001, the effective date was delayed until May 18, 2001, and at 66 FR 27599, May 18, 2001, the effective date was further delayed until Nov. 14, 2001. For the convenience of the user, the revised text is set forth as follows:</P>
      <REVTXT>
        <SUBPART>
          <HD SOURCE="HED">Subpart B—Additional Protections for Pregnant Women and Human Fetuses Involved in Research, and Pertaining to Human In Vitro Fertilization</HD>
          <SECTION>
            <SECTNO>§ 46.201</SECTNO>
            <SUBJECT>To what do these regulations apply?</SUBJECT>
            <P>(a) Except as provided in paragraph (b) of this section, this subpart applies to all research involving pregnant women or human fetuses, and to all research involving the in vitro fertilization of human ova, conducted or supported by the Department of Health and Human Services (DHHS). This includes all research conducted in DHHS facilities by any person and all research conducted in any facility by DHHS employees.</P>
            <P>(b) The exemptions at § 46.101(b)(1) through (6) are applicable to this subpart.</P>
            <P>(c) The provisions of § 46.101(c) through (i) are applicable to this subpart. Reference to State or local laws in this subpart and in § 46.101(f) is intended to include the laws of federally recognized American Indian and Alaska Native Tribal Governments.</P>
            <P>(d) The requirements of this subpart are in addition to those imposed under the other subparts of this part.</P>
          </SECTION>
          <SECTION>
            <SECTNO>§ 46.202</SECTNO>
            <SUBJECT>Definitions.</SUBJECT>
            <P>The definitions in § 46.102 shall be applicable to this subpart as well. In addition, as used in this subpart:</P>
            <P>(a) <E T="03">Dead fetus</E> means a fetus after delivery that exhibits neither heartbeat, spontaneous respiratory activity, spontaneous movement of voluntary muscles, nor pulsation of the umbilical cord. Delivery means complete separation of the fetus from the woman by expulsion or extraction or any other means.</P>
            <P>(b) <E T="03">Fetus</E> means the product of conception from implantation until a determination is made after delivery that it is viable.</P>
            <P>(c) <E T="03">In vitro fertilization</E> means any fertilization of human ova which occurs outside the body of a female, either through admixture of donor human sperm and ova or by any other means.</P>
            <P>(d) <E T="03">Nonviable fetus</E> means a fetus after delivery that, although living, is not viable.</P>
            <P>(e) <E T="03">Pregnancy</E> encompasses the period of time from implantation until delivery. A woman shall be assumed to be pregnant if she exhibits any of the pertinent presumptive signs of pregnancy, such as missed menses, until the results of a pregnancy test are negative or until delivery.</P>
            <P>(f) <E T="03">Secretary</E> means the Secretary of Health and Human Services and any other officer or employee of the Department of Health and Human Services to whom authority has been delegated.</P>
            <P>(g) <E T="03">Viable</E> as it pertains to the fetus means being able, after delivery, to survive (given the benefit of available medical therapy) to the point of independently maintaining heartbeat and respiration. The Secretary may from time to time, taking into account medical advances, publish in the <E T="04">Federal Register</E> guidelines to assist in determining whether a fetus is viable for purposes of this subpart. If a fetus after delivery is viable then it is a child as defined by § 46.402(a), and subpart D of this part is applicable.</P>
          </SECTION>
          <SECTION>
            <SECTNO>§ 46.203</SECTNO>
            <SUBJECT>Duties of IRBs in connection with research involving pregnant women, fetuses, and human in vitro fertilization.</SUBJECT>
            <P>In addition to other responsibilities assigned to IRBs under this part, each IRB shall review research covered by this subpart and approve only research which satisfies the conditions of all applicable sections of this subpart and the other subparts of this part.</P>
          </SECTION>
          <SECTION>
            <SECTNO>§ 46.204</SECTNO>
            <SUBJECT>Research involving pregnant women or fetuses prior to delivery.</SUBJECT>
            <P>Pregnant women or fetuses prior to delivery may be involved in research if all of the following conditions are met:</P>
            <P>(a) Where scientifically appropriate, preclinical studies, including studies on pregnant animals, and clinical studies, including studies on nonpregnant women, have been conducted and provide data for assessing potential risks to pregnant women and fetuses;</P>
            <P>(b) The risk to the fetus is not greater than minimal, or any risk to the fetus which is greater than minimal is caused solely by interventions or procedures that hold out the prospect of direct benefit for the woman or the fetus;</P>
            <P>(c) Any risk is the least possible for achieving the objectives of the research;</P>
            <P>(d) The woman's consent or the consent of her legally authorized representative is obtained in accord with the informed consent provisions of subpart A of this part, unless altered or waived in accord with § 46.101(i) or § 46.116(c) or (d);</P>
            <P>(e) The woman or her legally authorized representative, as appropriate, is fully informed regarding the reasonably foreseeable impact of the research on the fetus or resultant child;</P>

            <P>(f) For children as defined in 45 CFR 46.402(a) who are pregnant, assent and permission are obtained in accord with the provisions of subpart D of this part;<PRTPAGE P="120"/>
            </P>
            <P>(g) No inducements, monetary or otherwise, will be offered to terminate a pregnancy;</P>
            <P>(h) Individuals engaged in the research will have no part in any decisions as to the timing, method, or procedures used to terminate a pregnancy; and</P>
            <P>(i) Individuals engaged in the research will have no part in determining the viability of a fetus.</P>
          </SECTION>
          <SECTION>
            <SECTNO>§ 46.205</SECTNO>
            <SUBJECT>Research involving fetuses after delivery.</SUBJECT>
            <P>(a) After delivery, fetuses may be involved in research if all of the following conditions are met:</P>
            <P>(1) Where scientifically appropriate, preclinical and clinical studies have been conducted and provide data for assessing potential risks to fetuses.</P>
            <P>(2) The individual(s) providing consent under paragraph (b)(2) or (c)(5) of this section is fully informed regarding the reasonably foreseeable impact of the research on the fetus or resultant child.</P>
            <P>(3) No inducements, monetary or otherwise, will be offered to terminate a pregnancy.</P>
            <P>(4) Individuals engaged in the research will have no part in any decisions as to the timing, method, or procedures used to terminate a pregnancy.</P>
            <P>(5) Individuals engaged in the research will have no part in determining the viability of a fetus.</P>
            <P>(6) The requirements of paragraph (b) or (c) of this section have been met as applicable.</P>
            <P>(b) Fetuses of uncertain viability. After delivery, and until it has been ascertained whether or not a fetus is viable, a fetus may not be involved in research covered by this subpart unless the following additional conditions are met:</P>
            <P>(1) The IRB determines that:</P>
            <P>(i) The research holds out the prospect of enhancing the probability of survival of the particular fetus to the point of viability, and any risk is the least possible for achieving the objectives of the research, or</P>
            <P>(ii) The purpose of the research is the development of important biomedical knowledge which cannot be obtained by other means and there will be no risk to the fetus resulting from the research; and</P>
            <P>(2) The legally effective informed consent of either parent of the fetus or, if neither parent is able to consent because of unavailability, incompetence, or temporary incapacity, the legally effective informed consent of either parent's legally authorized representative is obtained in accord with subpart A of this part, unless altered or waived in accord with § 46.101(i) or § 46.116(c) or (d).</P>
            <P>(c) Nonviable fetuses. After delivery, a nonviable fetus may not be involved in research covered by this subpart unless all of the following additional conditions are met:</P>
            <P>(1) Vital functions of the fetus will not be artificially maintained;</P>
            <P>(2) The research will not terminate the heartbeat or respiration of the fetus;</P>
            <P>(3) There will be no risk to the fetus resulting from the research;</P>
            <P>(4) The purpose of the research is the development of important biomedical knowledge that cannot be obtained by other means; and</P>
            <P>(5) The legally effective informed consent of both parents of the fetus is obtained in accord with subpart A of this part, except that the waiver and alteration provisions of § 46.116(c) and (d) do not apply. However, if either parent is unable to consent because of unavailability, incompetence, or temporary incapacity, the informed consent of one parent of a nonviable fetus will suffice to meet the requirements of this paragraph. The consent of a legally authorized representative of either or both of the parents of a nonviable fetus will not suffice to meet the requirements of this paragraph.</P>
            <P>(d) Viable fetuses. A fetus, after delivery, that has been determined to be viable is a child as defined by § 46.402(a) and may be included in research only to the extent permitted by and in accord with the requirements of subparts A and D of this part.</P>
          </SECTION>
          <SECTION>
            <SECTNO>§ 46.206</SECTNO>
            <SUBJECT>Research involving, after delivery, the placenta, the dead fetus, or fetal material.</SUBJECT>
            <P>(a) Research involving, after delivery, the placenta; the dead fetus; macerated fetal material; or cells, tissue, or organs excised from a dead fetus, shall be conducted only in accord with any applicable Federal, State, or local laws and regulations regarding such activities.</P>
            <P>(b) If information associated with material described in paragraph (a) of this section is recorded for research purposes in a manner that living individuals can be identified, directly or through identifiers linked to those individuals, those individuals are research subjects and all pertinent subparts of this part are applicable.</P>
          </SECTION>
          <SECTION>
            <SECTNO>§ 46.207</SECTNO>
            <SUBJECT>Research not otherwise approvable which presents an opportunity to understand, prevent, or alleviate a serious problem affecting the health or welfare of pregnant women or fetuses.</SUBJECT>
            <P>The Secretary will conduct or fund research that the IRB does not believe meets the requirements of § 46.204 only if:</P>
            <P>(a) The IRB finds that the research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of pregnant women or fetuses; and</P>

            <P>(b) The Secretary, after consultation with a panel of experts in pertinent disciplines (for example: science, medicine, ethics, law) and following opportunity for public review <PRTPAGE P="121"/>and comment, including a public meeting announced in the <E T="04">Federal Register</E>, has determined either:</P>
            <P>(1) That the research in fact satisfies the conditions of § 46.204, as applicable, or</P>
            <P>(2) The following:</P>
            <P>(i) The research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of pregnant women or fetuses;</P>
            <P>(ii) The research will be conducted in accord with sound ethical principles; and</P>
            <P>(iii) Informed consent will be obtained in accord with the informed consent provisions of subpart A and other applicable subparts of this part, unless altered or waived in accord with § 46.101(i) or § 46.116(c) or (d).</P>
          </SECTION>
        </SUBPART>
      </REVTXT>
    </EFFDNOTP>
  </SECTION>
</CFRGRANULE>
